RPL22L1, a component of the 60S subunit regulated by RPL22, has been found to be significantly upregulated in glioblastoma (GBM) and hepatocellular carcinoma (HCC), leading to a poorer outcome for patients [7, 8]. Here, RPL22L1 is linked to hepatocellular carcinoma.